

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S
Form 6-K
February 26, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

February 26, 2008

NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)

NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____

TREASURY STOCK

ON 31 JANUARY 2008 NOVO NORDISK INITIATED ITS SHARE REPURCHASE PROGRAMME IN
ACCORDANCE WITH THE PROVISIONS OF THE EUROPEAN COMMISSION'S REGULATION NO
2273/2003 OF 22 DECEMBER 2003, ALSO REFERRED TO AS THE SAFE HARBOUR RULES.

Under the programme Novo Nordisk will repurchase B shares for an amount of up to
DKK 2 billion in the period from 31 January 2008 to 6 August 2008.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Since the announcement as of 18 February 2008, the following transactions have been made under the programme:

	NUMBER OF SHARES	AVERAGE PURCHASE PRICE	TRANSACTION VALUE, DKK
ACCUMULATED, LAST ANNOUNCEMENT	722,907		229,847,248
18 Feb 2008	50,000	331.78	16,589,000
19 Feb 2008	50,000	334.18	16,709,000
20 Feb 2008	50,000	332.84	16,642,000
21 Feb 2008	50,000	339.09	16,954,500
22 Feb 2008	25,000	341.42	8,535,500
ACCUMULATED, 2008	947,907		305,277,248

With the transactions stated above, Novo Nordisk owns a total of 25,917,260 treasury shares, corresponding to 4.0% of the share capital. The total amount of shares in the company is 646,960,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:

Outside North America:
Elin K Hansen
Tel: (+45) 4442 3450
ekh@novonordisk.com

In North America:
Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com

Investors:

Outside North America:
Mads Veggerby Lausten
Tel: (+45) 4443 7919
mlau@novonordisk.com

Hans Rommer
Tel: (+45) 4442 4765
hrrmm@novonordisk.com

In North America:
Christian Qvist Frandsen
Tel: (+1) 609 919 7937
cqfr@novonordisk.com

Stock Exchange Announcement no 12 / 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 26, 2008

NOVO NORDISK A/S

Lars Rebien Sorensen,

Edgar Filing: NOVO NORDISK A S - Form 6-K

President and Chief Executive Officer